Log in

NASDAQ:ZEAL - ZEALAND PHARMA/S Stock Price, Forecast & News

$29.25
+0.30 (+1.04 %)
(As of 03/29/2020 02:00 AM ET)
Today's Range
$28.69
Now: $29.25
$29.25
50-Day Range
$23.86
MA: $35.18
$45.00
52-Week Range
$17.02
Now: $29.25
$44.60
Volume5,783 shs
Average Volume13,801 shs
Market Capitalization$1.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.86
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH; and Alexion Pharmaceuticals, Inc. for the discovery and development of peptide therapies for complement-mediated diseases. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
Read More
ZEALAND PHARMA/S logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZEAL
CUSIPN/A
Phone45-8877-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.20 million
Book Value$5.85 per share

Profitability

Net Income$-85,670,000.00

Miscellaneous

Employees149
Market Cap$1.05 billion
Next Earnings Date5/21/2020 (Estimated)
OptionableNot Optionable

Receive ZEAL News and Ratings via Email

Sign-up to receive the latest news and ratings for ZEAL and its competitors with MarketBeat's FREE daily newsletter.


ZEALAND PHARMA/S (NASDAQ:ZEAL) Frequently Asked Questions

How has ZEALAND PHARMA/S's stock been impacted by COVID-19 (Coronavirus)?

ZEALAND PHARMA/S's stock was trading at $28.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ZEAL stock has increased by 4.1% and is now trading at $29.2479. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ZEALAND PHARMA/S?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZEALAND PHARMA/S in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ZEALAND PHARMA/S.

When is ZEALAND PHARMA/S's next earnings date?

ZEALAND PHARMA/S is scheduled to release its next quarterly earnings announcement on Thursday, May 21st 2020. View our earnings forecast for ZEALAND PHARMA/S.

What price target have analysts set for ZEAL?

5 Wall Street analysts have issued 1 year target prices for ZEALAND PHARMA/S's shares. Their forecasts range from $38.00 to $42.00. On average, they anticipate ZEALAND PHARMA/S's share price to reach $40.33 in the next year. This suggests a possible upside of 37.9% from the stock's current price. View analysts' price targets for ZEALAND PHARMA/S.

Has ZEALAND PHARMA/S been receiving favorable news coverage?

Media headlines about ZEAL stock have trended negative on Sunday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ZEALAND PHARMA/S earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutZEALAND PHARMA/S.

Who are some of ZEALAND PHARMA/S's key competitors?

What other stocks do shareholders of ZEALAND PHARMA/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ZEALAND PHARMA/S investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Ryder System (R), Pandora Media (P), Tandem Diabetes Care (TNDM), Ford Motor (F), Wells Fargo & Co (WFC), NVIDIA (NVDA), Alibaba Group (BABA) and Tesla (TSLA).

Who are ZEALAND PHARMA/S's key executives?

ZEALAND PHARMA/S's management team includes the following people:
  • Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Director (Age 66)
  • Dr. Emmanuel Dulac Ph.D., PharmD, MBA, CEO & Pres (Age 49)
  • Mr. Ivan Mourits Møller, Interim CFO and Sr. VP of Technical Devel. & Operations (Age 47)
  • Dr. Andrew Parker, Exec. VP & Chief Science Officer (Age 54)
  • Lani Pollworth Morvan, Investor Relations & Communications Officer

When did ZEALAND PHARMA/S IPO?

(ZEAL) raised $75 million in an IPO on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is ZEALAND PHARMA/S's stock symbol?

ZEALAND PHARMA/S trades on the NASDAQ under the ticker symbol "ZEAL."

Who are ZEALAND PHARMA/S's major shareholders?

ZEALAND PHARMA/S's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.09%), Jane Street Group LLC (0.04%) and Rockefeller Capital Management L.P. (0.03%).

Which institutional investors are buying ZEALAND PHARMA/S stock?

ZEAL stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Rockefeller Capital Management L.P., and Jane Street Group LLC.

How do I buy shares of ZEALAND PHARMA/S?

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ZEALAND PHARMA/S's stock price today?

One share of ZEAL stock can currently be purchased for approximately $29.25.

How big of a company is ZEALAND PHARMA/S?

ZEALAND PHARMA/S has a market capitalization of $1.05 billion and generates $6.20 million in revenue each year. The company earns $-85,670,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. ZEALAND PHARMA/S employs 149 workers across the globe. View additional information about ZEALAND PHARMA/S.

What is ZEALAND PHARMA/S's official website?

The official website for ZEALAND PHARMA/S is http://www.zealandpharma.com/.

How can I contact ZEALAND PHARMA/S?

ZEALAND PHARMA/S's mailing address is SMEDELAND 36 GLOSTRUP, COPENHAGEN G7, 2600. The company can be reached via phone at 45-8877-3600 or via email at [email protected]


MarketBeat Community Rating for ZEALAND PHARMA/S (NASDAQ ZEAL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  274 (Vote Outperform)
Underperform Votes:  279 (Vote Underperform)
Total Votes:  553
MarketBeat's community ratings are surveys of what our community members think about ZEALAND PHARMA/S and other stocks. Vote "Outperform" if you believe ZEAL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZEAL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: Percentage Decliners

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel